Akèy › Myelom Miltip › Pennsylvania › Philadelphia
Etid klinik pou Myelom Miltip nan Philadelphia, PA
16 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Philadelphia (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Ap rekriteFaz 1
- University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Ap rekriteFaz 4
- University of Pennsylvania, Philadelphia
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Penn Medicine, Philadelphia
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Fox Chase Cancer Center, Philadelphia
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Ap rekriteFaz 1/2
- Research Site, Philadelphia
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Ap rekriteFaz 3
- Thomas Jefferson University Hospital, Philadelphia
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- University of Pennsylvania, Philadelphia
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
Ap rekriteFaz 1/2
- ECOG-ACRIN Cancer Research Group, Philadelphia
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Ap rekriteFaz 1/2
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Ap rekrite
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Ap rekriteFaz 3
- Abramson Cancer Center University of Pennsylvania Medical Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Ap rekriteFaz 2
- Thomas Jefferson University Hospital, Philadelphia
Limited-duration Teclistamab
Ap rekriteFaz 2
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
- Thomas Jefferson University, Honickman Center, Philadelphia
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
Lòt etid nan Philadelphia
- Kansè (tout kalite)59 etid
- Kansè nan tete56 etid
- Kansè Poumon ki pa ti selil51 etid
- Kansè Metastatik46 etid
- Kansè kolorektal44 etid
- Kansè ovè44 etid
- Kansè pwostat44 etid
- Kansè poumon36 etid
- Leksemi mieloïd egi34 etid
- Ensifizyans kadyak31 etid
- Kansè Endomèt28 etid
- Depresyon26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.